Daiichi Sankyo To Develop New General Purpose Vaccine Adjuvant
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has begun developing a new general purpose vaccine adjuvant on June 1 as a collaborative development project at the Japan Science and Technology Agency, the company announced on June 11.